argenx SE
adimanebart
myositis
Countdown
86days
Phase 1 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 1 trial results for adimanebart in myositis are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 10h ago
“Follow-up results from the Phase 1b study of adimanebart, a MuSK agonist antibody, in DOK7 CMS showed that improvements in key QMG components and six-minute walk test performance (total distance and cadence), observed during the 12-week tre”